CN109641057A - 用于治疗子宫内膜异位症的剂量方案 - Google Patents

用于治疗子宫内膜异位症的剂量方案 Download PDF

Info

Publication number
CN109641057A
CN109641057A CN201780050282.8A CN201780050282A CN109641057A CN 109641057 A CN109641057 A CN 109641057A CN 201780050282 A CN201780050282 A CN 201780050282A CN 109641057 A CN109641057 A CN 109641057A
Authority
CN
China
Prior art keywords
dosage regimen
fluoro
methylene
triazol
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780050282.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·帕金
L·B·克里克斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merio Biopharmaceutical Second Co Ltd
Original Assignee
Merio Biopharmaceutical Second Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merio Biopharmaceutical Second Co Ltd filed Critical Merio Biopharmaceutical Second Co Ltd
Publication of CN109641057A publication Critical patent/CN109641057A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780050282.8A 2016-08-19 2017-08-21 用于治疗子宫内膜异位症的剂量方案 Pending CN109641057A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1614179.8A GB201614179D0 (en) 2016-08-19 2016-08-19 Dosage regimen for the treatment of endometriosis
GB1614179.8 2016-08-19
PCT/GB2017/052466 WO2018033759A1 (en) 2016-08-19 2017-08-21 Dosage regimen for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
CN109641057A true CN109641057A (zh) 2019-04-16

Family

ID=57045488

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780050282.8A Pending CN109641057A (zh) 2016-08-19 2017-08-21 用于治疗子宫内膜异位症的剂量方案

Country Status (6)

Country Link
US (1) US20190192485A1 (https=)
EP (1) EP3500305A1 (https=)
JP (1) JP2019524846A (https=)
CN (1) CN109641057A (https=)
GB (1) GB201614179D0 (https=)
WO (1) WO2018033759A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12552754B1 (en) 2025-06-11 2026-02-17 ReproNovo SA Leflutrozole compositions of matter and processes for preparation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637605A (en) * 1990-12-12 1997-06-10 Ciba Geigy Corporation α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
WO2004069260A1 (en) * 2003-02-05 2004-08-19 Astrazeneca Ab Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
WO2013036563A1 (en) * 2011-09-08 2013-03-14 Novartis Ag Pharmaceutical compositions comprising an aromatase inhibitor
CN103002873A (zh) * 2010-03-31 2013-03-27 拜耳知识产权有限责任公司 用于治疗子宫内膜异位症的释放芳香化酶抑制剂和孕激素的肠外剂型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637605A (en) * 1990-12-12 1997-06-10 Ciba Geigy Corporation α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
WO2004069260A1 (en) * 2003-02-05 2004-08-19 Astrazeneca Ab Compositon comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
CN103002873A (zh) * 2010-03-31 2013-03-27 拜耳知识产权有限责任公司 用于治疗子宫内膜异位症的释放芳香化酶抑制剂和孕激素的肠外剂型
WO2013036563A1 (en) * 2011-09-08 2013-03-14 Novartis Ag Pharmaceutical compositions comprising an aromatase inhibitor
US20140213622A1 (en) * 2011-09-08 2014-07-31 Novartis Ag Pharmaceutical compositions comprising an aromatse inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LISA L. AMSTERDAM等: ""Anastrazole and oral contraceptives: a novel treatment for endometriosis"", 《FERTILITY AND STERILITY》 *
SUBRATA LALL SEAL等: ""Aromatase inhibitors in recurrent ovarian endometriomas: report of five cases with literature review"", 《FERTILITY AND STERILITY》 *
丰靖卿等: ""子宫内膜异位症药物治疗现状及研究进展"", 《赣南医学院学报》 *
王景叶等: ""复方口服避孕药的非避孕作用"", 《中国临床药学杂志》 *

Also Published As

Publication number Publication date
EP3500305A1 (en) 2019-06-26
US20190192485A1 (en) 2019-06-27
GB201614179D0 (en) 2016-10-05
JP2019524846A (ja) 2019-09-05
WO2018033759A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
DK2552404T3 (en) PARENTERAL PHARMACEUTICAL FORM RELEASING AROMATASE INHIBITORS AND GESTAGENES FOR TREATMENT OF ENDOMETRIOSIS
EP1359920B1 (en) Uses of oral formulations for the treatment of female sexual dysfunction
CN105979935B (zh) 包含雌四醇组分的口崩固体剂量单位
JPH02502724A (ja) 避妊を達成する組成物および方法
CN101626760A (zh) 利用递增剂量长周期给药方案进行激素治疗的方法
RU2628808C2 (ru) Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний
JP2003527416A (ja) 結合型エストロゲンと酢酸メドロキシプロゲステロンとの組合せを用いたホルモン補充療法
BG65849B1 (bg) Дроспиренон за хормонзаместваща терапия
EA028780B1 (ru) Применение эстетрола в качестве экстренного контрацептива
AU2003210757B2 (en) Method of hormonal therapy
CN109641057A (zh) 用于治疗子宫内膜异位症的剂量方案
JP2006522833A (ja) エストロゲンおよびプロゲスチンの投与法
WO2018011015A1 (en) Low-dosed oral dosage forms for treatment of diseases
WO2003082299A1 (en) Improved hormone replacement therapy
Rahman et al. 7 Injectable Longer Action Reversible Contraception
WO2009112232A2 (en) New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
EP2647378A1 (en) Steroid sulfatase inhibitor regimen for the treatment of endometriosis
TW200942242A (en) New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190416

WD01 Invention patent application deemed withdrawn after publication